Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04HQT
|
||||
| Former ID |
DIB020758
|
||||
| Drug Name |
proglumide
|
||||
| Synonyms |
Milid; Nulsa; W-5219
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H26N2O4
|
||||
| InChI |
InChI=1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22)
|
||||
| InChIKey |
DGMKFQYCZXERLX-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
5236624, 7848880, 8149717, 8153032, 10321573, 11335859, 11361098, 11364226, 11366788, 11369350, 11372506, 11373889, 11377512, 11462070, 11466268, 11467388, 11485188, 11485976, 11489222, 11491259, 11492240, 11495146, 14777663, 17405393, 26612175, 26680275, 26747589, 26747590, 29224000, 47515325, 47662292, 47810761, 47810762, 47810763, 47885426, 48110460, 48185002, 48416475, 49698766, 49834543, 49972990, 50106676, 50106677, 50226741, 53777938, 56463359, 57288819, 57322526, 85088918, 85231119
|
||||
| Target and Pathway | |||||
| Target(s) | Cholecystokinin receptor type A | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Insulin secretion | |||||
| Pancreatic secretion | |||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 893). | ||||
| REF 2 | Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung. 1987 Nov;37(11):1265-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.